Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | CNR2 | P34972 | 3/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 14/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878098 | 0.86 | EPHX2 (0.67) | FAAHCNR2EPHX2MEN1KMT2A | |
| SCHEMBL4881073 | 0.81 | FAAH (0.68) | FAAHCNR2EPHX2CNR1ALDH1A1 | |
| SCHEMBL14162080 | 0.78 | EPHX2 (0.52) | FAAHCNR2EPHX2MEN1KMT2A | |
| SCHEMBL4878185 | 0.77 | FAAH (0.80) | FAAHCNR2EPHX2CNR1MEN1 | |
| SCHEMBL15009560 | 0.76 | TRPV6 (0.66) | FAAHCNR2EPHX2MEN1KMT2A | |
| SCHEMBL4882753 | 0.76 | EPHX2 (1.00) | FAAHCNR2EPHX2ALDH1A1 | |
| SCHEMBL14086737 | 0.75 | EPHX2 (1.00) | FAAHCNR2EPHX2ALDH1A1 | |
| SCHEMBL4255244 | 0.75 | EPHX2 (0.73) | FAAHCNR2EPHX2 | |
| SCHEMBL19798449 | 0.74 | KMT2A (0.72) | FAAHCNR2EPHX2MEN1ALDH1A1 | |
| SCHEMBL2166377 | 0.74 | ALOX5 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | FAAH 4/4885CNR2 1338/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.